Interview with MVI's Director of R&D

Rick King, PhD, looks at challenges and opportunities in malaria vaccine development and discusses the thinking behind MVI’s work in anti-infection and transmission-blocking vaccines.

Read more »

Loading samples ©  F. Beilhe

Photo credit: F. Beilhe

World Malaria Report 2014 Key Figures

Partnering with us

PuzzleWe are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.

Our portfolio

MVI portfolioWe maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.

View the portfolio »Subscription button

What we do and how we do it

MVI overview imageWe identify potentially promising malaria vaccine approaches and systematically move them through the development process. At the same time, we work to catalyze access to a successful malaria vaccine in the countries that need it most.

Read more »


 

News and announcements

Walking together: Steve Davis reflects on 15 years of Gavi partnership

This week on Gavi’s blog, Steve Davis, president and CEO of PATH, provided insight on what it takes to develop and strengthen a global community of scientists, policymakers, advocates, regulators, medical workers, and caregivers to continue our good work.

 

Malaria vaccine gets a shot in the arm

MVI announces $156 million grant from Bill & Melinda Gates Foundation to support essential vaccine role in strategy to eradicate malaria.

 

Japan's Global Health Innovative Technology Fund announces award to MVI

MVI welcomes announcement by Japan’s Global Health Innovative Technology Fund of a grant to MVI and its partner Ehime University to fast-track the development of a novel malaria vaccine candidate. The new vaccine approach is targeted at blocking malaria parasite transmission between humans and mosquitoes.

 

GSK announces EU regulatory submission for RTS,S malaria vaccine candidate

The regulatory application to the European Medicines Agency (EMA) will follow the Article 58 procedure, which allows the EMA to assess the quality, safety and efficacy of a candidate vaccine, or medicine, manufactured in a European Union (EU) member state for a disease recognized by the World Health Organization as of major public health interest, but intended exclusively for use outside the EU.

 

Events and Conferences

Global Conference on Vaccines
April 13–15, 2015